Advancing Meningitis Management: Role of Polymeric Nanoparticles in Drug Delivery and Diagnostics

Introduction: Meningitis is an inflammatory condition affecting the brain and spinal cord, commonly resulting from bacterial infections. Even with advancements in antimicrobial treatments, it still leads to significant illness and death because of difficulties in penetrating the Blood-Brain Barrier (BBB). Polymeric Nanoparticles (PNPs) are becoming a promising option, providing targeted drug delivery to improve brain bioavailability while minimising adverse effects. Methods: A literature search was conducted across databases including PubMed, SciDirect, Google Scholar, Wiley Online Library, and ClinicalTrials.gov. Keywords such as "Meningitis," "Nanoparticles," "Blood-Brain Barrier," and "Bacterial Infections" were utilised to identify pertinent studies published from 2015 to 2024. The search encompassed peer-reviewed articles, clinical trials, and patents. The latest search took place in January 2025, focusing on high-quality, open-access studies. Results: Research emphasises how PNPs can improve drug delivery across the BBB, leading to better treatment outcomes for meningitis. Clinical trials and patents indicate encouraging outcomes for nanoparticle formulations in achieving targeted and sustained drug release. Innovative methods such as convection-enhanced delivery and focused ultrasound are being investigated to improve the delivery of nanoparticles. Discussion: The use of PNPs in treating meningitis has demonstrated the potential to improve drug delivery through the blood-brain barrier, thereby enhancing therapeutic outcomes while minimizing systemic side effects. However, implementing these findings in clinical settings is challenging due to issues such as changes in BBB integrity during infection, the limited predictive accuracy of existing animal models, and the necessity for thorough safety evaluations. Conclusion: Polymeric nanoparticles offer a promising approach for both the treatment and diagnosis of meningitis, effectively addressing the challenges posed by the blood-brain barrier. Although initial trials show promise, additional research is needed to refine the formulations and confirm their effectiveness. These developments align with the WHO’s Global Roadmap to defeat meningitis by 2030.